Search

An introduction is presented in which the editor discusses various reports within the issue including human error as a citation among companies as a cause of deviation with a subsequent corrective and preventive action, a review of the new European Medicines Agency (EMA) Draft Guideline on Sterilisation of the Medicinal Product and anti-counterfeiting and sterilisation issue.

Medicinal cannabis and respective products have been available in EU member states as single-patient prescriptions without regular marketing authorizations for a couple of years. The Netherlands was the first member state to realize this; in the meantime other member states have followed. Today, aside from the Netherlands, Germany is the most important market for such products. The regulatory framework for the approval of medicinal cannabis and its distribution to patients in the EU member states is, however, not harmonized at all, and there are distinct national regulations. Regarding the quality of such products, the general requirements for herbal medicinal products as defined in the European Pharmacopoeia, national pharmacopoeias, and the EMA guidance documents in place beside GMP requirements in the EU are applicable. However, for a couple of aspects, every EU member state follows its own interpretation of these requirements. To facilitate free distribution of such products between EU member states in future and to harmonize requirements for quality and GMP, an EU-wide approach is needed. As a first step, this should be realized by implementing monographs for cannabis medicinal products in the European Pharmacopoeia. [ABSTRACT FROM AUTHOR]

The article explores efforts to regulate gene therapies by health authorities. Several of these health authorities are discussed including the European Medicines Agency (EMA) and the US Food and Drug Administration (FDA). Additional topics discussed include the small number of deaths attributed to gene therapy, the first trials of gene editing inside the body, and how the EMA and FDA both use data-driven approaches to assessing drug safety and advocacy.

A report from the Institute for Scientific Freedom in Copenhagen, Denmark discusses their efforts to retrieve conflicts of interest declarations from the European Medicines Agency (EMA) over a period of three years. The researchers submitted Freedom of Information requests to access EMA's lists of committee members involved in drafting guidelines for psychiatric indications. After almost three years, the EMA provided member lists and conflicts of interest declarations from the Committee for Medicinal Products for Human use (CHMP) for three requested guidelines. The report recommends that the EMA improve transparency by publishing author names and conflicts of interest declarations directly in the guidelines. [Extracted from the article]

The article highlights the companies included in the Change the World list of "Fortune" magazine for 2015. They include telecommunications companies Vodafone and Safaricom, Internet giant Google and retailer Walmart. Vodafone and Safaricom created the mobile-money platform M-Pesa, which is said to have transformed the regional economy in Kenya. Google's commitment to fostering academic collaboration through its services such as Google Scholar, and Walmart's focus on sustainability are tackled.

A table is presented that summarises the status of all the parts of set of updated ISO 14644 series of standards for cleanrooms and associated clean environments including classification of air cleanliness, test methods and biocontamination control. It also mentions a concept paper issued by European Medicines Agency recommending the revision of the Annexure 1 of the European Union (EU) Good Manufacturing Practices (GMP) Guidelines on the manufacturing of sterile products.

The Regional Bank note of the Year Awards, part of the High Security Printing EMEA Conference recently held in Malta, have been conferred on winners in three categories: best new series; best new bank note; and best new commemorative bank... [ABSTRACT FROM AUTHOR]

The article investigates the risks with drugs that are being rushed to market after limited testing. Topics covered are the approval of drugs based on preliminary findings, international ramifications of approvals made by the U.S. Food and Drug Administration (FDA) or European Medicines Agency (EMA), FDA's accelerated approval for bimatorpost for eyelash growth, EMA's granting of conditional marketing authorization to new drugs and expedited approval of cancer drugs.

The article discusses the development in the regulations in the pharmaceutical industry. It talks about the European Medicines Agency's (EMA) mission to protect human and animal health, and also ensure safe access to quality medicines. It states that implementation of Good Manufacturing Practice (GMP) has to be ensured. It is noted that the U.S. Food and Drug Administration (FDA) is amending its regulations on drug establishment registration and listing.

The article offers information on developments in the regulations of the pharmaceutical industry. Topics discussed include the European Medicines Agency starting to review the guidelines that describe first-in-human clinical trials and the data needed to enable their appropriate design and allow initiation, the EU Good Manufactuing Practices needed for sterilisation processes of primary packaging and introduction and implementation of safety features on packaging.

The article outlines some regulatory updates for pharmaceutical industries in the European Union (EU) and the U.S. as of January 2016. Topics discussed include the agreement signed by the European Medicines Agency and the World Health Organization (WHO) to share confidential information to protect global public health, and regulations related to Qualified Persons. Also mentioned is the U.S. Food and Drug Administration directive that revises permitted daily exposure of workers to solvents.

The article presents companies featured in the new Change the World list of "Fortune" magazine, companies that have made progress in addressing major social problems as part of their core business strategy. Topics discussed include changes in lives and businesses in Kenya made by M-Pesa mobile-money platform created by telecommunications companies Vodafone and Safaricom, information provided by Internet search company Google, and hybrid cars like Prius and Mirai of automaker Toyota.

Novavax hit another roadblock in its COVID-19 vaccine journey in the U.S., with the company pushing back an FDA filing from May to July to now the fourth quarter. The company filed in India, Indonesia and the Philippines this week, and expects more submissions later this year with WHO, UK, EU, Australia, Canada and New Zealand. [ABSTRACT FROM AUTHOR]

The European Medicines Agency management board has nominated Emer Cook to be the next executive director of the agency. Cooke, who works at the World Health Organization, will replace Guido Rasi later in the year if she comes through the remaining steps in the hiring process. [ABSTRACT FROM AUTHOR]

The article reports the approval of the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) for using pharmaceutical company Gedeon Richter's Esmya tablets for the treatment of uterine fibroids.